Showing 2561-2570 of 5771 results for "".
- Aerie Announces Positive Phase 2b Study Results for Dry Eye Product Candidatehttps://modernod.com/news/aerie-announces-positive-phase-2b-study-results-for-dry-eye-product-candidate/2480279/Aerie Pharmaceuticals reported positive topline results of its phase 2b clinical study, COMET-1, for AR-15512 (TRPM8 agonist) ophthalmic solution for the treatment of patients with dry eye disease. The randomized, double-masked, vehicle-controlled phase 2b clinical study
- Retina Consultants of America Announces Addition of Tennessee Retinahttps://modernod.com/news/retina-consultants-of-america-announces-addition-of-tennessee-retina/2479505/Retina Consultants of America (RCA), a physician management services organization, has added Tennessee Retina, which operates nine locations that include Nashville, Bowling Green, and Crossville. The addition of Tennessee Retina marks RCA’s first entry into Tennessee and the surrounding region. <
- Hi-Health Announces Elevated Quality Process for Vista Advanced Supplementshttps://modernod.com/news/hi-health-announces-elevated-quality-process-for-vista-advanced-supplements/2479392/Hi-Health’s eye care brand, Vista OTC, is manufactured in cGMP certified and FDA regulated facilities. Hi-Health released a news release providing additional information about its quality standar
- PYC Therapeutics Announces Preclinical Results Demonstrating VP-002 Program’s Potential as the First Disease Modifying Therapy for Autosomal Dominant Optic Atrophyhttps://modernod.com/news/pyc-therapeutics-announces-comprehensive-preclinical-results-demonstrating-vp-002-programs-potential-as-the-first-disease-modifying-therapy-for-autosomal-dominant-optic-atrophy/2479330/PYC Therapeutics released a summary of preclinical findings supporting the potential of PYC’s VP-002 program as the first disease-modifying therapy for patients suffering from Autosomal Dominant Optic Atrophy (ADOA). PYC’s PPMO technology used in the VP-002 program significantly increases levels
- Zeiss Celebrates 175th Anniversary in 2021https://modernod.com/news/zeiss-celebrates-175th-anniversary-in-2021/2479194/Zeiss’ success story began 175 years ago, in a small workshop. On November 17, 1846, young mechanic Carl Zeiss opened his workshop for precision mechanics and optics in Jena, thus laying the foundation for what would become today’s global technology player Zeiss. Zeiss went on to join
- Ceyeber Announces Advisory Board of World-Renowned Ophthalmologistshttps://modernod.com/news/ceyeber-announces-advisory-board-of-world-renowned-ophthalmologists/2479167/Ceyeber, the developer of implantable intraocular lens technology designed for medical applications and augmented reality, has created a Medical Advisory Board consisting of top ophthalmologists. Ceyeber’s founder and CEO, Robert E. Grant, said, “
- Lexitas Announces George N. Magrath, MD, MBA Assumes Role of Chief Executive Officerhttps://modernod.com/news/lexitas-announces-george-n-magrath-md-mba-assumes-role-of-chief-executive-officer/2478905/George N. Magrath, MD, MBA, MS, has been named CEO of Lexitas Pharma Services. Chad Ice will transition from the role as CEO to President with a focus on strategic growth initiatives as well as the expansion of the Lexitas Board of Directors. These changes became effective February 1, 2021. <
- Optimo Medical and Ansys Partner Announce Partnership to Improve Surgery Preparationhttps://modernod.com/news/optimo-medical-and-ansys-partner-announce-partnership-to-improve-surgery-preparation/2478904/Optimo Medical and Ansys are incorporating high-fidelity structural simulations with digital twin technology into next-generation surgery preparation, according to a company news release. The collaboration also drives in silico clinical trials of new eye products, with the aim of significantly re
- Life Biosciences Announces Research in Nature Describing New Mechanisms for Reversing Age-Related Diseasehttps://modernod.com/news/life-biosciences-announces-research-in-nature-describing-new-mechanisms-for-reversing-age-related-disease/2478889/Life Biosciences has in-licensed intellectual property related to scientific findings recently described in two publications in the journal Nature. The publications, based on research conducted in animal models, report that therapies targeting the biology of aging have the potential to not
- Regenxbio Announces Additional Positive Interim Phase 1/2a and Long-Term Follow-Up Data of RGX-314 for the Treatment of Wet AMDhttps://modernod.com/news/regenxbio-announces-additional-positive-interim-phase-1-2a-and-long-term-follow-up-data-of-rgx-314-for-the-treatment-of-wet-amd/2478873/Regenxbio reported additional positive interim data from Cohorts 4 and 5 of its RGX-314 phase 1/2a trial for the treatment of wet age-related macular degeneration (AMD), and Cohort 3 of its Long-Term Follow-Up (LTFU) study. RGX-314 is a potential best-in-class, one-time gene therapy for the treat